ETNB May 2024 10.000 put
| Previous close | 1.3800 |
| Open | 1.3800 |
| Bid | 0.8500 |
| Ask | 2.4500 |
| Strike | 10.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.3800 - 1.3800 |
| Contract range | N/A |
| Volume | |
| Open interest | 31 |
GlobeNewswire89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ETSAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event of pegozafermin’s opportunity in advanced metabolic dysfunction-associated
- GlobeNewswire
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024. Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer
- GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 138,550 shares of the Company’s common stock to eight new em
